Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Key facts

Sponsor

Everest Medicines (China) Co.,Ltd.

Intervention

EVER001(drug)

Enrollment

30 enrolled

Eligibility

18-75 years · All sexes

Timeline

2023 – 2026

Study locations (19)

• The Second Xiangya Hospital Of Central South University, Changsha, Changsha, China
• The First Affiliated Hospital of PLA Army Medical University, Chongqing, Chongqing Municipality, China
• The Third Affiliated Hospital,Sun Yat Sen University, Guangzhou, Guangdong, China
• Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
• The Second Affiliated Hospital of Harbin Medical University, Harbin, Harbin, China
• Xiangya Third Hospital, Central South University, Changsha, Hunan, China
• The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China
• Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
• The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
• The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
• The First Affiliated Hospital of Medical college of Xi'an Jiaotong University, Xian, Shanxi, China
• Sichuan Province People's Hospital, Chengdu, Sichuan, China
• Second Hospital of Shanxi Medical University, Shanxi, Taiyuan, China
• The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
• +4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary membranous glomerulonephritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07289763
  Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
  Guangdong Hengrui Pharmaceutical Co., Ltd
• RECRUITINGPHASE2, PHASE3NCT07204275
  A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
  Vertex Pharmaceuticals Incorporated
• RECRUITINGPHASE2NCT07157787
  Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
  Alexion Pharmaceuticals, Inc.
• RECRUITINGPHASE2NCT07096843
  A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
  Climb Bio, Inc.
• RECRUITINGPHASE3NCT06962800
  A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
  Biogen
• RECRUITINGPHASE1NCT06982729
  Study of YK012 in Primary Membranous Nephropathy
  Excyte Biopharma Ltd
• RECRUITINGNCT06242327
  An Outcome Analysis of Primary Membranous Nephropathy
  Mario Negri Institute for Pharmacological Research
• ACTIVE NOT RECRUITINGPHASE2NCT06642909
  A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
  BioRay Pharmaceutical Co., Ltd.

See all trials for Primary membranous glomerulonephritis →